Abbott Laboratories Stock

When dividend stocks are struggling and trading at reduced valuations, there's a big incentive to load up on them. At lower share prices, not only could they generate better returns, but their

Abbott Laboratories (NYSE: ABT) is offering income investors a rare setup: a yield is approaching 3% while the business continues to grow. The stock isn't a screaming bargain, and rising costs

Investing in high-quality dividend stocks is a great way to earn excellent returns over the long run. It's even better to buy shares of attractive dividend payers on the dip. That's what investors

These are times that can make an investor nervous. Our country is waging a war, while tariffs have disrupted the global economy, with some trade partnerships changing. With so much seemingly

Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one another in the market for continuous glucose monitoring (CGM) systems.

Abbott Laboratories (NYSE: ABT) more or less met analyst estimates in its first quarter, the results of which were published early Thursday morning. This clearly wasn't good enough for investors, as

Economic downturns cast a wide net across the market, and there's no stock that's completely immune to a recession. However, certain income-oriented healthcare stocks can help investors weather

Stocks that perform well over the long run tend to have several traits, such as a large, growing market where they have a strong presence, solid financial results, and a competitive moat. Investing

Abbott Laboratories (NYSE: ABT), a medical device specialist, recently fell off a cliff after a disappointing quarterly update that missed consensus top-line estimates. The healthcare giant is

Over the past few years, the exciting field of artificial intelligence (AI) has captured much of Wall Street's attention and headlines. And sure enough, some of the leaders in AI have produced

You may not immediately recognize the name Abbott Laboratories (NYSE: ABT), but you've probably come into close contact with one of the company's many products -- from a coronavirus test to Ensure

Shares of Abbott Laboratories (NYSE: ABT) recently plunged after the company announced its fourth-quarter results. Over the trailing 12 months, the stock is down 16%. Some might choose to stay away

Abbott Laboratories (NYSE: ABT) announced its 2025 fourth-quarter and full-year results before the market opened on Thursday, Jan. 22, 2026. And its shares promptly plunged nearly 10%. As you

It might not seem like it, but the S&P 500 flirted with bear market territory earlier this year. It has rebounded nicely since, but it's always worth considering which stocks would be worth buying

No one knows how the stock market will unfold in 2026. Perhaps broader equities will experience significant volatility but perform well by the end of the year, just as they seem to be doing in 2025

Abbott Laboratories (NYSE: ABT), a medical device specialist, has a lot going its way. The company has a large and diversified portfolio of products, which it routinely expands through new launches

Shares of Exact Sciences (NASDAQ: EXAS) climbed on Thursday after the medical diagnostics specialist agreed to be acquired by Abbott (NYSE: ABT) for $21 billion.

As of 2:30 p.m. EST, Exact

News of an apparently impending sale to a strategic investor sent shares of Exact Sciences (NASDAQ: EXAS) skyward on Wednesday. The cancer diagnostics specialist's shares closed the day nearly 24%